2010
DOI: 10.4049/jimmunol.1090051
|View full text |Cite
|
Sign up to set email alerts
|

Anti-TNF Therapy, from Rationale to Standard of Care: What Lessons Has It Taught Us?

Abstract: In the mid-1980s, new molecular tools enabled the biology of cytokine expression and regulation to be studied. Our group uncovered a TNF-dependent cascade in active rheumatoid synovium, suggesting that TNF might be a therapeutic target; this concept was supported in an animal model of the disease. The proof of concept was a series of clinical trials, which have led to marked changes in the therapy of human rheumatoid arthritis and subsequently of other diseases. The work with TNF clearly demonstrated the impor… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
56
0
2

Year Published

2010
2010
2023
2023

Publication Types

Select...
10

Relationship

2
8

Authors

Journals

citations
Cited by 93 publications
(59 citation statements)
references
References 35 publications
1
56
0
2
Order By: Relevance
“…Anti-TNF antibody was the first cytokine-selective therapy that was shown to offer clear benefits in the setting of common disease in rheumatoid arthritis, being both effective and acceptably safe (44). Based upon our data, prophylaxis with anti-TNF antibody is a feasible therapeutic option that is ready to be exploited in the elective surgical setting.…”
Section: Discussionmentioning
confidence: 82%
“…Anti-TNF antibody was the first cytokine-selective therapy that was shown to offer clear benefits in the setting of common disease in rheumatoid arthritis, being both effective and acceptably safe (44). Based upon our data, prophylaxis with anti-TNF antibody is a feasible therapeutic option that is ready to be exploited in the elective surgical setting.…”
Section: Discussionmentioning
confidence: 82%
“…In this respect, TNF-a is a central mediator of multiple aspects of synovial inflammation that can activate fibroblasts, osteoclasts, B, and T cells and is an established therapeutic target in JIA (23). IFN-g may also play a pathogenic role by activating macrophages, whereas IL-17 increases vascularization and induces influx of neutrophils to drive inflammation (24,25).…”
Section: Discussionmentioning
confidence: 99%
“…However, these observations regarding the kinetics of clinical translation have held equally valid for other therapeutic approaches that have been investigated in multiple animal models of autoimmunity. For example, while TNFα blockade in rheumatoid arthritis and IBD [112], and α4β1 integrin blockade in MS [113], reached clinical practice relatively soon after initial investigations in relevant animal models, clinical translation of anti-CD3 therapy in T1D has proven to be a longer and more challenging path. However, the sluggish translation of findings from the NOD mouse to clinical practice does not necessarily constitute a comment on the clinical relevance of findings in this model so much as a testament to the unique challenges of developing novel therapies for T1D.…”
Section: Discussionmentioning
confidence: 99%